Elanco

Investor Alert: Lawsuit Filed Against Elanco Animal Health for Alleged Securities Law Violations

by

New York — A prominent securities law firm, Bleichmar Fonti & Auld LLP, has filed a lawsuit against Elanco Animal Health Incorporated and some of its top executives alleging violations of federal securities laws. This legal action, initiated in the U.S. District Court of Maryland, addresses concerns within the financial community regarding the company’s recent disclosures. The lawsuit, officially noted as Barpar v. Elanco Animal Health Incorporated, et al., Case No. 24-cv-02912, claims misconduct under specific sections of the Securities Exchange Act of 1934, reflecting the interests of stakeholders in Elanco’s securities. The focus of … Read more

Elanco Animal Health Sued Over Alleged Misleading Claims About New Drug Zenrelia’s Safety and Launch Prospects

by

San Francisco, Oct. 17, 2024 – A recently filed securities class action lawsuit claims that Elanco Animal Health misled its investors about the regulatory path and safety profile of their new dermatology medication, Zenrelia. The legal action targets both the organization and specific upper-level employees for allegedly providing false or misleading information to investors between November 7, 2023, and June 26, 2024. The lawsuit, registered in the U.S. District Court of Maryland, elaborates that Elanco downplayed the safety concerns associated with Zenrelia, an oral Janus kinase inhibitor. Furthermore, the company was overly optimistic about its … Read more